Project R-2307

Validation of advanced, macrophage-targeted vaccines for MS (Research)

Recently, a new receptor was identified as a protein exclusively expressed on specific immune cells. Because of the important role of these immune cells in the immune system, targeted manipulation of these cells via this receptor might be promising in steering immunity. Therefore, we are developing a technology that can either provoke, subtly modify or completely eradicate an immune response. To evaluate if the technology can be used for treatment of multiple sclerosis (MS), we aim to study expression levels of this receptor on immune cells in a rat model of MS. In addition, preclinical targeting of the receptor will be performed in this model. This project will elucidate whether this technology can result in a better and safer treatment of MS.

01 January 2010 - 31 December 2012